Fu Laimei (polyethylene glycol loxenatide) / Jiangsu Hansoh Pharma 
Welcome,         Profile    Billing    Logout  
 5 Diseases   3 Trials   3 Trials   34 News 
  • ||||||||||  Victoza (liraglutide) / Novo Nordisk, Fu Laimei (polyethylene glycol loxenatide) / Jiangsu Hansoh Pharma, Ozempic (semaglutide SC once-weekly) / Novo Nordisk
    Journal, Real-world evidence, Real-world effectiveness, Real-world:  Real-world effectiveness of GLP-1 receptor agonist-based treatment strategies on "time in range" in patients with type 2 diabetes. (Pubmed Central) -  Mar 22, 2024   
    These real-world findings indicate that GLP-1RA-based treatment strategies could be superior to oral treatment strategies for improving TIR among patients with T2DM and that once-weekly GLP-1RA may be more effective than a once-daily GLP-1RA. Clinical trial registration: http://www.chinadrugtrials.org.cn/index.html, identifier number ChiCTR2300073697.
  • ||||||||||  Fu Laimei (polyethylene glycol loxenatide) / Jiangsu Hansoh Pharma
    Retrospective data, Review, Journal:  Role of Novel Glucagon-like Peptide-1 Receptor Analogue Polyethylene Glycol Loxenatide in Type 2 Diabetes: A Systematic Review and Meta-analysis. (Pubmed Central) -  Dec 18, 2023   
    Occurrence of nausea [RR 16.85 (95% CI: 3.89 to 72.92); P < 0.01; I = 10%], vomiting [RR 15.90 (95% CI: 2.99 to 84.55); P < 0.01; I = 0%], and anorexia [RR 3.85 (95% CI: 1.24 to 11.88); P = 0.02; I = 0%] was significantly higher with high-dose peg-loxenatide, as compared to placebo. Peg-loxenatide (100 mcg/week) is the most appropriate dose for clinical use as it is associated with good glycaemic efficacy with minimal gastro-intestinal side effects.
  • ||||||||||  Fu Laimei (polyethylene glycol loxenatide) / Jiangsu Hansoh Pharma, Ozempic (semaglutide SC once-weekly) / Novo Nordisk
    Cost-Effectiveness Analysis of Once-Weekly Semaglutide Versus Polyethylene Glycol Loxenatide for Treatment of Type 2 Diabetes in China (Virtual) -  Sep 1, 2022 - Abstract #ISPOREU2022ISPOR_EU_1695;    
    Clinicians can rationally choose and use drugs according to the patient's conditions and needs. Compared with treatment with PEG-Loxenatide, once-weekly semaglutide represents a dominant option for treating patients with T2D in China who are not achieving glycemic control with metformin, projected to both improve clinical outcomes and reduce costs.
  • ||||||||||  Fu Laimei (polyethylene glycol loxenatide) / Jiangsu Hansoh Pharma
    Enrollment open:  Loxenatide Plus LNG-IUS in Endometrial Atypical Hyperplasia (clinicaltrials.gov) -  Jan 19, 2022   
    P2/3,  N=28, Recruiting, 
    PEX-168 may regulate the expression of chemerin and omentin through its hypoglycaemic effect, and the weight-reducing effect of PEX-168 is unlikely to be the reason for the changes in both. Not yet recruiting --> Recruiting
  • ||||||||||  polyethylene glycol loxenatide (PEX168) / Jiangsu Hansoh Pharma
    Clinical, PK/PD data, Journal:  Polyethylene glycol loxenatide (PEX168) in subjects with renal impairment: A pharmacokinetic study. (Pubmed Central) -  Sep 30, 2020   
    P1
    A single dose of 200 μg of PEX168 was in general well tolerated in patients with renal impairment. The in vivo clearance rate of PEX168 in patients with moderate renal impairment is slower than in patients with mild renal impairment and normal renal function and dose adjustment might be required (ClinicalTrials.org #NCT02467790).
  • ||||||||||  Fu Laimei (polyethylene glycol loxenatide) / Jiangsu Hansoh Pharma
    Trial primary completion date, Monotherapy:  Efficacy and Safety Study of PEX168 in Monotherapy Diabetes Mellitus Type 2 Patients (clinicaltrials.gov) -  Jan 24, 2017   
    P3,  N=406, Active, not recruiting, 
    The in vivo clearance rate of PEX168 in patients with moderate renal impairment is slower than in patients with mild renal impairment and normal renal function and dose adjustment might be required (ClinicalTrials.org #NCT02467790). Trial primary completion date: Jan 2016 --> May 2016
  • ||||||||||  Fu Laimei (polyethylene glycol loxenatide) / Jiangsu Hansoh Pharma
    Trial primary completion date, Monotherapy:  Efficacy and Safety Study of PEX168 in Monotherapy Diabetes Mellitus Type 2 Patients (clinicaltrials.gov) -  Jan 26, 2016   
    P3,  N=406, Active, not recruiting, 
    Recruiting --> Completed | Trial primary completion date: Dec 2015 --> Sep 2015 Trial primary completion date: Sep 2015 --> Jan 2016
  • ||||||||||  Fu Laimei (polyethylene glycol loxenatide) / Jiangsu Hansoh Pharma
    Enrollment closed, Trial primary completion date:  Evaluate the Pharmacokinetics of Simvastatin When Coadministered With PEX168 in Healthy Adult Subjects (clinicaltrials.gov) -  Jan 26, 2016   
    P1,  N=16, Active, not recruiting, 
    Trial primary completion date: Sep 2015 --> Mar 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2015 --> May 2016